Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
batefenterol + fluticasone furoate
- Development stage
- Discontinued
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
Batefenterol + fluticasone furoate is a fixed-dose combination drug that was developed for the treatment of chronic obstructive pulmonary disease (COPD). Batefenterol acts as both a beta 2 adrenergic receptor agonist and a muscarinic receptor antagonist, providing bronchodilation through dual mechanisms. Fluticasone furoate is an inhaled corticosteroid that acts as a glucocorticoid receptor agonist, reducing airway inflammation. The combination was intended to provide comprehensive management of COPD symptoms by targeting bronchoconstriction and inflammation simultaneously. Development was led by GSK (GlaxoSmithKline) in collaboration with Innoviva (formerly Theravance). Clinical development for COPD has been discontinued[4].
- Other names
- Batefenterol and fluticasone furoate combination
02
Targets
mAChR (Muscarinic acetylcholine receptors)GR (Glucocorticoid receptor)ADRB2 (β2)
Beyond the preview
Go deeper on batefenterol + fluticasone furoate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on batefenterol + fluticasone furoate.